Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

237 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
New driver mutations in non-small-cell lung cancer.
Pao W, Girard N. Pao W, et al. Lancet Oncol. 2011 Feb;12(2):175-80. doi: 10.1016/S1470-2045(10)70087-5. Lancet Oncol. 2011. PMID: 21277552 Review.
Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer.
Lovly CM, McDonald NT, Chen H, Ortiz-Cuaran S, Heukamp LC, Yan Y, Florin A, Ozretić L, Lim D, Wang L, Chen Z, Chen X, Lu P, Paik PK, Shen R, Jin H, Buettner R, Ansén S, Perner S, Brockmann M, Bos M, Wolf J, Gardizi M, Wright GM, Solomon B, Russell PA, Rogers TM, Suehara Y, Red-Brewer M, Tieu R, de Stanchina E, Wang Q, Zhao Z, Johnson DH, Horn L, Wong KK, Thomas RK, Ladanyi M, Pao W. Lovly CM, et al. Nat Med. 2014 Sep;20(9):1027-34. doi: 10.1038/nm.3667. Epub 2014 Aug 31. Nat Med. 2014. PMID: 25173427 Free PMC article.
Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms tumors.
Polosukhina D, Love HD, Correa H, Su Z, Dahlman KB, Pao W, Moses HL, Arteaga CL, Lovvorn HN 3rd, Zent R, Clark PE. Polosukhina D, et al. Mol Oncol. 2017 Apr;11(4):405-421. doi: 10.1002/1878-0261.12044. Epub 2017 Mar 15. Mol Oncol. 2017. PMID: 28188683 Free PMC article.
ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma.
Hutchinson KE, Johnson DB, Johnson AS, Sanchez V, Kuba M, Lu P, Chen X, Kelley MC, Wang Q, Zhao Z, Kris M, Berger MF, Sosman JA, Pao W. Hutchinson KE, et al. Oncotarget. 2015 Sep 8;6(26):22348-60. doi: 10.18632/oncotarget.4255. Oncotarget. 2015. PMID: 26084293 Free PMC article.
NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor.
Galvani E, Sun J, Leon LG, Sciarrillo R, Narayan RS, Sjin RT, Lee K, Ohashi K, Heideman DA, Alfieri RR, Heynen GJ, Bernards R, Smit EF, Pao W, Peters GJ, Giovannetti E. Galvani E, et al. Oncotarget. 2015 Dec 15;6(40):42717-32. doi: 10.18632/oncotarget.3956. Oncotarget. 2015. PMID: 26015408 Free PMC article.
Epidermal growth factor receptor as a novel molecular target for aggressive papillary tumors in the middle ear and temporal bone.
Kawabata S, Hollander MC, Munasinghe JP, Brinster LR, Mercado-Matos JR, Li J, Regales L, Pao W, Jänne PA, Wong KK, Butman JA, Lonser RR, Hansen MR, Gurgel RK, Vortmeyer AO, Dennis PA. Kawabata S, et al. Oncotarget. 2015 May 10;6(13):11357-68. doi: 10.18632/oncotarget.3605. Oncotarget. 2015. PMID: 26027747 Free PMC article.
EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer.
Amato KR, Wang S, Tan L, Hastings AK, Song W, Lovly CM, Meador CB, Ye F, Lu P, Balko JM, Colvin DC, Cates JM, Pao W, Gray NS, Chen J. Amato KR, et al. Cancer Res. 2016 Jan 15;76(2):305-18. doi: 10.1158/0008-5472.CAN-15-0717. Epub 2016 Jan 7. Cancer Res. 2016. PMID: 26744526 Free PMC article.
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ, Hughes G, Rahi A, Jacobs VN, Red Brewer M, Ichihara E, Sun J, Jin H, Ballard P, Al-Kadhimi K, Rowlinson R, Klinowska T, Richmond GH, Cantarini M, Kim DW, Ranson MR, Pao W. Cross DA, et al. Cancer Discov. 2014 Sep;4(9):1046-61. doi: 10.1158/2159-8290.CD-14-0337. Epub 2014 Jun 3. Cancer Discov. 2014. PMID: 24893891 Free PMC article.
Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.
Walter AO, Sjin RT, Haringsma HJ, Ohashi K, Sun J, Lee K, Dubrovskiy A, Labenski M, Zhu Z, Wang Z, Sheets M, St Martin T, Karp R, van Kalken D, Chaturvedi P, Niu D, Nacht M, Petter RC, Westlin W, Lin K, Jaw-Tsai S, Raponi M, Van Dyke T, Etter J, Weaver Z, Pao W, Singh J, Simmons AD, Harding TC, Allen A. Walter AO, et al. Cancer Discov. 2013 Dec;3(12):1404-15. doi: 10.1158/2159-8290.CD-13-0314. Epub 2013 Sep 24. Cancer Discov. 2013. PMID: 24065731 Free PMC article.
Maximizing the benefits of off-target kinase inhibitor activity.
Red Brewer M, Pao W. Red Brewer M, et al. Cancer Discov. 2013 Feb;3(2):138-40. doi: 10.1158/2159-8290.CD-12-0581. Cancer Discov. 2013. PMID: 23400472
237 results
Jump to page
Feedback